Sabby Capital

RooLife Group specializes in connecting premium lifestyle brands with consumers worldwide through digital marketing and customer acquisition services. Leveraging AI-driven personalization, they facilitate direct online sales of products across food, beverage, health, and wellness categories.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Ardelyx is a biopharmaceutical company developing first-in-class, minimally absorbed oral medicines to treat mineral metabolism and metabolic disorders. Based in Fremont, California, founded in 2007. It focuses on non-systemic therapies that act in the intestines to modulate transporters and receptors, aiming to limit systemic exposure. Its lead product Tenapanor targets irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease on dialysis; the program includes Phase 3 trials. The company is pursuing additional candidates such as RDX013 for hyperkalemia, and RDX002 and RDX009 in earlier stages. Ardelyx aims to address cardiorenal and metabolic conditions using a non-systemic platform.

Champions Oncology, Inc. is a biotechnology company that specializes in developing and selling technology solutions aimed at personalizing oncology drug development and treatment. Headquartered in Hackensack, New Jersey, the company utilizes its Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice, to deliver Personalized Oncology Solutions (POS). These solutions aid physicians in crafting tailored treatment plans by providing tumor-specific data from drug panels. Additionally, Champions Oncology offers Translational Oncology Solutions (TOS) that support pharmaceutical and biotechnology companies in their drug development processes. The company's product offerings include TumorGraft implants and drug panels that evaluate how a patient's tumor responds to various oncology drugs or combinations. Founded in 1985 and previously known as Champions Biotechnology, Inc., Champions Oncology is committed to enhancing cancer treatment outcomes through innovative technologies.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for underserved patient communities, particularly those affected by blood disorders. The company is advancing its lead product candidate, Oxbryta (voxelotor), which is an oral, once-daily therapy designed for the treatment of sickle cell disease (SCD). Oxbryta has completed Phase III clinical trials in adult and adolescent patients and is currently being evaluated for safety and pharmacokinetics in a Phase IIa trial involving pediatric patients. In addition to its efforts in SCD, Global Blood Therapeutics is engaged in research and development for other blood-related conditions, including hereditary angioedema, and holds licensed rights to its product candidates in multiple regions, including the United States and Europe.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops targeted, small-molecule therapies to treat genomically defined cancers, rare diseases, and related conditions. The company focuses on precision medicines that address molecular drivers and resistance mechanisms, advancing a pipeline that includes avapritinib for systemic mastocytosis and certain gastrointestinal stromal tumors, BLU-263, a KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders, fisogatinib for advanced hepatocellular carcinoma, and pralsetinib, a RET inhibitor for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. It is also pursuing BLU-782, an ALK2 inhibitor in early clinical trials for fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with partner companies such as Clementia Pharmaceuticals, CStone Pharmaceuticals, Genentech, and Hoffmann-La Roche. Founded in 2008, the company operates in the United States and Europe and combines its Insights-to-Validation platform with a proprietary chemical library to discover and develop new therapeutic compounds and combination therapies in oncology, hematology, and related areas.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.

Dermira, Inc. is a biopharmaceutical company that specializes in developing and commercializing therapies for dermatologic diseases, primarily targeting the U.S. market. Founded in 2010 and headquartered in Menlo Park, California, Dermira offers QBREXZA, a topical treatment for primary axillary hyperhidrosis in patients aged nine and older. The company is also advancing its pipeline with lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, alongside several other early-stage research initiatives in dermatology. Dermira has established strategic partnerships for the development and commercialization of its products, including agreements with Maruho Co., Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., and UCB Pharma S.A. Notably, Dermira was previously known as Skintelligence, Inc. before rebranding in September 2011. As of early 2020, Dermira operates as a subsidiary of Eli Lilly and Company.

Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. Headquartered in Redwood City, California, the company aims to establish gene therapy as a new standard of care, aspiring to provide functional cures that restore vision and prevent blindness. Its pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-term therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with partners like Editas Medicine and Regeneron Pharmaceuticals to leverage advanced AAV vectors and develop treatments for various inherited retinal diseases and ocular therapeutic targets. Founded in 2006, the company was previously known as Avalanche Biotechnologies and rebranded in 2016.

Stem Cell Therapeutics Corp. is a Toronto-based biopharmaceutical development company focused on advancing cancer stem cell research into innovative therapies for cancer treatment. As Canada's only public company dedicated to this field, it leverages over fifty years of pioneering stem cell research and collaborates with leading academic institutions and oncology treatment centers in Toronto, a prominent hub for cancer research. Additionally, the company develops drug-based therapies aimed at treating central nervous system diseases. These therapies stimulate the patient's own resident stem cells to repair neurological functions impaired by conditions such as stroke, traumatic brain injury, and multiple sclerosis, ultimately providing potential cures for various nervous system disorders.

Arno Therapeutics, Inc. is a biopharmaceutical company based in Flemington, New Jersey, dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's product pipeline includes Onapristone, a type 1 anti-progestin hormone blocker currently undergoing Phase I/II clinical studies for various solid tumors, including breast and endometrial cancers in post-menopausal women and advanced castration-resistant prostate cancer in men. Additionally, Arno is advancing AR-12, an orally available cancer treatment that has completed Phase I studies for solid tumors and hematological malignancies, as well as AR-42, another oral therapy currently in Phase I investigator-initiated studies targeting hematological malignancies and solid tumors. The company has established collaboration agreements with several institutions, enhancing its research and development efforts.